"8th Annual General Meeting Entero Healthcare Solutions Limited"

August 19, 2026

Management: Mr. Sujesh Vasudevan – Chairman

Mr. Prabhat Agrawal – Managing Director & Chief Executive Officer & Chairman of Risk Management Committee

Mr. Rajesh Dalal – Independent Director & Chairman of the Nomination and Remuneration Committee & Stakeholders Relationship Committee

Mr. Prem Sethi – Whole-time Director & Chief Operating Officer

Ms. Sandhya Gadkari Sharma – Independent Director & Chairperson of the Audit Committee

Mr. Arun Sadhanandham – Non-Executive Nominee Director

Ms. Sumona Chakraborty – Non-Executive Nominee Director

Mr. Balakrishnan Kaushik – Chief Financial Officer

Ms. Sanu Kapoor – Group General Counsel & Company Secretary

Sanu Kapoor: Good afternoon, dear members and all other participants. I, Sanu Kapoor, Group General Counsel & Company Secretary, welcome you all to the 8th Annual General Meeting of Entero Healthcare Solutions Limited. This AGM is being held through video conferencing or other audio-visual means in accordance with the Companies Act 2013, the SEBI Listing Regulations, and the circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India, without the physical presence of the members at a common venue. The proceedings of this meeting are being recorded for compliance purposes. A live streaming of this meeting is also being webcast on the website of NSDL, that is, National Securities Depository Limited. The company has taken all requisite steps to enable the members to participate in this AGM and to vote electronically on the business items set out in the AGM notice. Since the AGM is being held through video conferencing, the facility for appointment of proxies by members is not applicable. The Annual Report for the financial year 2025-26, containing the Board's Report, standalone and consolidated financial statements, Statutory Auditors' Reports, and other reports, together with the notice convening the 8th AGM, have already been sent electronically to all members whose email addresses are registered with the company, RTA, depository participants. The requisite newspaper advertisements have also been published. The notice and Annual Report are being available on the company's website and may also be accessed on the websites of BSE, NSE, and NSDL. Physical copies of the Annual Report have been dispatched to the members who requested the same. Further, letters containing the web link for accessing the Annual Report on the company's website have been sent to members whose email addresses are not registered. The Statutory Registers as required under the Companies Act 2013, and the certificate issued by the Secretarial Auditor relating to the implementation of ESOP scheme, and other documents referred to in the AGM notice are available for electronic inspection by members. In compliance with the provisions of the Companies Act 2013 and SEBI Listing Regulations, the company has provided the facility of remote e-voting through the NSDL platform to all members holding shares as on the cut-off date, that is, 12th August, 2026. Remote e-voting commenced at 9:00 a.m. IST on Sunday, 16th August, 2026, and concluded at 5:00 p.m. IST on Tuesday, 18th August, 2026. The facility for e-voting during this meeting is also available to members participating in the AGM who have not already cast their votes through remote e-voting. The e-voting platform is now open, and such members may cast their votes electronically on all the business items set out in the AGM notice during the course of this meeting. The e-voting facility will also remain open for 15 minutes at the end of the meeting to enable eligible members who have not yet voted to cast their votes. Mr. Avinash Bagul or failing him, Mr. Ramaswami Kalidas of M/s BNP & Associates, Company Secretaries, has been appointed as the Scrutinizer to scrutinize the remote e-voting and e-voting at the meeting in a fair and transparent manner. The Scrutinizer's report on the consolidated results of remote e-voting and e-voting conducted during the meeting will be submitted within two working days from the conclusion of this meeting. The results, together with scrutinizer's reports, will be placed on the company's website, intimated to BSE and NSE, and made available on NSDL's website. I would now like to take the members through certain important instructions regarding participation in this meeting. Members joining the meeting are, by default, placed on mute mode by the host to avoid any disturbances caused by background noise and to ensure smooth and seamless conduct of the meeting. Members facing any technical difficulty while joining or participating may contact NSDL help desk. Once the question-and-answer session starts, the moderator will announce the names of the registered speaker shareholders in sequence, and their audio will be unmuted by the host. Speaker shareholders are requested to switch on their video by clicking on the video button and wait till video is enabled before speaking. If for any reason a speaker is unable to switch on the video, they may proceed through audio mode. In the interest of time, we request speaker shareholders to restrict their remarks to a maximum of 2 minutes. For better audio-visual experience, speaker shareholders are requested to use earphones, ensure stable network connectivity, close unnecessary applications running in the background, and ensure adequate lighting. In the event of any connectivity issue at a speaker shareholder's end, the next speaker shareholder will be invited to speak. Once their connectivity is restored, the concerned speaker shareholder will be invited again after the other registered speaker shareholders complete their turn. Speaker shareholders are requested to keep their remarks brief and relevant to the business of the meeting, and to refrain from sharing any personal, sensitive, or confidential information. If any speaker shareholder is unable to join or speak due to technical difficulties, or if any query remains unaddressed during the meeting, the shareholder may write to the company at its designated investor email address, and the same will be responded by the company.

I would now like to hand over the proceedings to our Chairman, Mr. Sujesh Vasudevan. Over to you, sir.

Sujesh Vasudevan: Thank you, Sanu and good afternoon, ladies and gentlemen. It gives me immense pleasure to welcome you all to the 8th Annual General Meeting of the company. As the requisite quorum is present, I hereby call this meeting to order. Before we proceed, let me introduce my fellow Board Members, beginning with those who have joined the meeting through video conferencing. Mr. Arun Sadhanandham, Non-Executive Nominee Director, has joined the meeting from Mumbai, and Ms. Sumona Chakraborty, Non-Executive Nominee Director, has joined the meeting from Bangalore. And also present with me here in Mumbai are, Mr. Prabhat Agrawal, Managing Director and CEO and the Chairperson of Risk Management Committee, Ms. Sandhya Sharma, Independent Director and Chairperson of the Audit Committee, Mr. Rajesh Dalal, Independent Director and Chairperson of the Nomination and Remuneration Committee and Stakeholders Relationship Committee, Mr. Prem Sethi, Whole-time Director and Chief Operating Officer; Mr. Balakrishnan Kaushik, Chief Financial Officer; and Ms. Sanu Kapoor, our Company Secretary. Members of our leadership team are also attending this meeting through video conferencing. Representatives of M/s MSKA & Associates LLP, the statutory auditors, and M/s BNP & Associates, the secretarial auditors of the company, as well as the scrutinizer, are also attending the meeting. The company has received the necessary corporate authorizations from the corporate members for attending this meeting through their representatives. The notice convening this AGM, together with the annual report containing the Board's report and other reports, has already been circulated electronically to the members. With the permission of the members, I take this notice as read. The Statutory Auditors' reports on standalone and consolidated financial statements for the financial year ended 31st March, 2026, do not contain any qualification, observation, or comment on financial transactions or matters having any adverse effect on the functioning of the company. Accordingly, with the permission of the members, the statutory auditors' reports are taken as read. The Secretarial Audit Report for the financial year ended 31st March, 2026, also does not contain any qualification, reservation, adverse remark, or disclaimer. As all the business items set out in the AGM notice have already been put to vote through remote e-voting, hence there is no requirement for business items to be proposed or seconded at this meeting. I would now like to take you through a brief overview of your company. Entero was founded in 2018 with a vision to create an organized, pan-India, technology-driven, and integrated healthcare products distribution platform that can add value to the entire healthcare ecosystem. I share with a deep sense of pride that we have achieved and scaled new highs in a very short span of time. I am delighted to present Entero's FY25-'26 annual report as we accelerate on this journey with greater speed, scale, and purpose. Since our inception in 2018, Entero has grown multifold to emerge as one of India's leading pharmaceutical distribution organizations, a journey strengthening every pillar that defines this business. At the heart of this growth lies the relationships we have cultivated across the value chain, with our manufacturing partners who trust us to distribute their products with integrity, and with our customers who rely on us for reliability, range, and speed. These relationships are the foundation of a distribution ecosystem that works because every partner within it finds value. Equally, the depth and reach of our distribution network, spanning over 500 districts, more than 135 warehouses, and 1,05,000 retail customers, combined with technology infrastructure we have built to enable smarter, faster, and more reliable movement of healthcare products, has distinguished Entero as a leading player. But above all, it is our people, Enteroians, who are the true cornerstone of everything we have built. Their energy, their commitment, and their belief in what we are creating together is what converts strategy into execution and our ambition into reality. Every milestone that we celebrate is, at its core, a reflection of who they are and what they bring to this organization. This year, we took another strategic step forward, one that we believe will define the next chapter of Entero's growth. Through the strategic acquisitions of MedTech distribution segment, we built meaningful scale and an extension of our journey into MedTech that will echo our pharmaceutical distribution journey, entering a large, underpenetrated, fragmented, and a more profitable market for organizing, scaling, and leading. The opportunity ahead is substantial. India's MedTech distribution landscape bears a resemblance of pharmaceutical distribution. We will leverage our deep partnerships and the trust earned with retail and institutional customers to scale ahead. Looking ahead, we will consolidate and deepen integration of our MedTech acquisitions across the business. We will drive synergies across our pharmaceutical and MedTech distribution networks. Our focus remains unwavering on sharpening operational excellence across our distribution network and creating a long-term sustainable value for all our stakeholders. We embark on new horizons for growth, and most importantly, with a motivated team that has the ability to execute with speed and conviction. The investments we make today in people, technology, partnerships are the foundation for driving the next phase of Entero's growth. India's healthcare distribution landscape is at an inflection point, vast, underpenetrated, and ripe for organized and technology-driven transformation that Entero is uniquely positioned to lead. We bring to it the same conviction and the same sense of purpose that has made Entero what it is today. We are ready.

I would like to thank you for your continued trust and support. Now I request Mr. Prabhat Agrawal, Managing Director and CEO, to give his overview and share his insights on the affairs of the company.

Prabhat Agrawal: Thank you, Chairman. Good afternoon, ladies and gentlemen. I extend a very warm welcome to all our esteemed members and other participants joining us today at the Eighth Annual General Meeting of the company. I'll now briefly share an overview of the company's performance and key developments during the year. Financial year '26 has been a landmark year in Entero's journey. It was a year in which we demonstrated that growth, profitability and cash generation, all can be delivered simultaneously. More importantly, it was a year that validated our long-term vision of building India's most comprehensive, integrated and technology-enabled healthcare distribution platform. When we started this journey eight years ago, our objective was clear, to transform a highly fragmented healthcare supply chain into an organized, efficient and scalable ecosystem that creates value for every stakeholder. Today, as we reflect on financial year '26, we are proud of the progress we have made towards realizing that vision. Our performance during the year reflects the strength of our strategy and the disciplined execution of our teams. We delivered revenues of INR 6,591 crores, representing 29.3% year-on-year growth, which is 31.5% like-for-like growth, significantly ahead of industry growth rates. More importantly, we strengthened profitability, with EBITDA increasing 55% to INR266 crores, while EBITDA margins expanded from 3.4% to 4%. Profit after tax grew by 36% to INR 146 crores and for the first time, we generated INR96 crores in operating cash flow, marking a significant milestone in our evolution. These achievements are particularly meaningful because they reflect our ability to deliver on every commitment we made at the beginning of the year. We had outlined three priorities, achieving 30% revenue growth, reaching 4% EBITDA margins and generating positive operating cash flows. I am pleased to share that we delivered on all three. This outcome reinforces our confidence in the scalability of our business model and quality of the platforms we have built. But our story extends beyond financial performance. Over the years, Entero has evolved into India's largest healthcare distribution network. Today, our platform serves more than 1,05,300 retail pharmacies, 3,600 plus hospitals and healthcare providers across 523 districts, supported by a network of 136 warehouses. We provide access to 97,500 plus SKUs sourced from over 3,300 healthcare product manufacturers, enabling reliable and timely availability of healthcare products across the country. This scale is not merely a measure of size; it is a reflection of the trust placed in us by the manufacturers, healthcare providers, pharmacists, and patients. Every addition to our network strengthens our ability to improve healthcare accessibility across India. A defining milestone for financial year '26 has been our strategic expansion beyond pharmaceuticals into the rapidly growing MedTech sector. Through a combination of organic initiatives and three strategic acquisitions completed during the year, we have established a meaningful presence across diagnostic consumables and equipments, medical devices, cardiology, orthopedics and imaging-related products. The MedTech segment now contributes over INR1,000 crores in annualized revenue, broadening our addressable market and strengthening our position as a diversified healthcare distribution platform. Beyond revenue diversification, MedTech offers attractive growth opportunities, higher value-added distribution models and stronger margin profiles. We believe this segment will become an increasingly important contributor to Entero's long-term growth and profitability. Our acquisition strategy continues to remain disciplined and focused on value creation. During FY26, we completed seven strategic acquisitions that expanded our capabilities, geography and product category presence. Each acquisition was selected based on strategic fit, integration potential, and long-term shareholder value creation. As we move into the next phase of our journey, our focus will increasingly shift towards realizing synergies, enhancing operational efficiencies and maximizing returns from these investments. Alongside growth, we have remained focused on improving the quality of our growth and strengthening capital efficiency. Through disciplined inventory management, optimized procurement practices, improved collections and technology-led decision making, we reduced our net working capital cycle and generated meaningful improvements in cash flow generation. These efforts are reflected in our improving return metrics. During FY26, return on capital employed increased from 10.7% to 14.6%, while return on equity improved from 7.7% to 12.5%. Such improvements demonstrate our commitment to fostering sustainable growth while maintaining financial discipline. Technology continues to remain a critical pillar of our strategy. We operate in an industry where efficiency, speed and responsiveness are increasingly important. Our investments in digital infrastructure, data analytics, supply chain optimization and customer engagement platforms are helping us improve decision making, enhance productivity and create a more connected healthcare ecosystem. These capabilities not only support our current scale but also provide a strong foundation for future growth. As we look ahead, we do so with confidence and clarity. India's healthcare supply chain industry, estimated at over USD33 billion, remains highly fragmented, creating a significant consolidation opportunity for organized players. With the platform we have built, the relationships we have nurtured and the capabilities we continue to strengthen, we believe Entero is uniquely positioned to capitalize on this opportunity. For FY27, our focus will be on driving profitable growth, strengthening cash generation and further improving operational efficiency. Having completed a significant phase of acquisitions, we will focus on integration, synergy realization and unlocking the full potential of our extended platform. At Entero, we have always believed that the true scale is not measured by revenue alone. It is measured by the breadth of healthcare access we enable, the efficiency we bring to the ecosystem, the trust we build with our partners and the value we create for our stakeholders. FY26 has reinforced our belief that the future we envisioned is already taking shape. Next is now, and we are ready to lead the transformation of healthcare distribution in India. To all, to all our customers, partners, employees, shareholders and all stakeholders, I extend my heartfelt gratitude for your continued trust and support. Together, we will continue to expand horizons, create lasting value, and build a healthier future for millions. Thank you.

Sujesh Vasudevan: Thank you, Prabhat. I now request the moderator to call out the names of the speaker shareholders one by one.

Moderator: Thank you so much sir. Our first speaker shareholder, Mr. Gagan Kumar, kindly accept the prompt on your screen, turn on your audio and video, and you may please proceed ahead with the question.

Gagan Kumar: Am I audible?

Moderator: Yes, sir, you are. Please go ahead.

Gagan Kumar: Good afternoon, Mr. Chairman, Board of Directors and fellow shareholders. Myself Gagan Kumar. I am joining this meeting from Delhi. First of all, I would like to mention that I had requested for a hard copy of annual report, which I received well in time. And I am very happy to share that I do not have any questions pertaining to accounts, as each and every aspect of balance sheet is very much clear. And thank you so much to Chairman Sir and CFO Sir for the detailed explanation about our company's progress and future roadmap. My one or two general queries for today's AGM is that what steps are being taken to improve return for the shareholder and make the company more profitable? And what is our capex plan? Where do we see our company by 2030? And as our promoter holding is around 53%, can we expect any buyback from the management to enhance the same? And how is our order book, sir, for next quarter? These three, four queries of mine, and it would be unfair on my part without mentioning higher corporate governance under the leadership of our CFO, CS, and entire secretarial team. Not at the time of AGM or EGM, throughout the year, if we have any query, we are just a mail away. So, thank you so much for this kind of dynamic team we have. Thank you for the opportunity.

Moderator: Thank you. Our next speaker shareholder, Mr. Sarvjeet Singh, kindly accept the prompt on your screen, turn on your audio and video, and you may please proceed ahead with the question.

Sarvjeet Singh: Hello. Chairman sir, can you hear my voice?

Moderator: Yes, we can hear you, sir. Please proceed.

Sarvjeet Singh: Chairman sir, first of all, good afternoon to you, all the Board of Directors, all the staff of Entero Healthcare Limited, and my fellow shareholders. Sir, whatever you explained in the opening remarks, a lot was presented in that, and all the questions that usually arise were recovered by you in that itself. Apart from that, sir, what does an investor need? Sir, a return on their investment. Which, sir, in the share price, the way you people are working hard, in the same way, investors have been receiving returns. Apart from that, sir, our company's promoter holding is around 51%, so will we plan any buyback, etcetera, to increase it? Sir, please shed some light on this. Besides that, sir, what will be our roadmap for the next 24 months? Sir, please tell us a little about this. Apart from that, Chairman sir, CFO sir, Chairman sir, and the entire CS department, sir, I would like to thank them, who gave us the opportunity to speak in front of you so frequently. Thank you, sir. Thank you so much for giving me a chance to speak in your AGM.

Moderator: Thank you. Our next speaker shareholder, Mr. Lokesh Gupta, kindly accept the prompt on your screen, turn on your audio and video, and you may please proceed.

Lokesh Gupta: Chairman sir, I am Lokesh Gupta from Delhi. I welcome you and all the board members. Sir, an excellent chairman speech is taking place, in which you explained about the present and future of the company, after that, no questions remain. Questions are about trust and faith. Sir, we have trust and faith in you. The decisions you have taken for the company earlier and will take in the future will be in the interest of the company earlier as well and will be so in the future too. The company's performance is being reflected in the share price. Sir, I want to know, what are we doing to increase margins? Please tell us a little about this. Sir, there is one small request as well. Please consider a bonus, sir, so that shareholders can receive a bonus. Once a year, we get an opportunity to meet you, sir. For a lot of information, we go to the Company Secretary and her team, and we receive replies well in time, for which I would like to thank them. In the end, I extend best wishes for the prosperous future of the company. Thank you, sir.

Moderator: Thank you. Our next speaker shareholder, Ajay Kumar Jain, kindly accept the prompt on your screen, turn on your audio and video, and you may please proceed ahead with the question.

Ajay Kumar Jain: Hello. Greetings, Chairman sir. I am Ajay Kumar Jain speaking from Delhi, a shareholder of the company. Where you presented the projections and financials for 2025-26 in the AGM of the last year, you have delivered even better than that. For that, you, your leadership, and your entire team deserve congratulations. In the Chairman's speech and what the MD sir explained about the company, it raises hope that when the current financial year ends, we might see some good corporate action from the company, either in the form of dividend or in any other form, there is hope of good benefit to the shareholders from the company. There are one or two questions, sir. In the quarter that is currently underway, where does my company's financial growth stand compared to the last quarter? And, sir, how much is my company spending on AI technology, and how much benefit are they reaping from it? Please explain this. And sir, under your guidance, the Company Secretary did not treat the meeting as a mere formality, but discharged it with responsibility. The entire team followed up as well. They followed up yesterday, they followed up today, sent the balance sheet, and the host's signal quality is also coming very good. It feels as if I too am seated in the boardroom. A good event, a good company, a memorable moment. After listening to your words in the lunch session, whatever hunger the mind had was satisfied, and it felt that the coming time under your leadership is going to be very good for us. With this hope and trust, greetings, Jai Hind.

Moderator: Thank you so much, sir. Our next speaker shareholder, Mr. Manjit Singh, kindly accept the prompt on your screen, turn on your audio and video, and you may please proceed ahead with the question.

Manjit Singh: Am I audible?

Moderator: Yes, sir, you are.

Manjit Singh: The management team of Entero Healthcare, secretarial team, and my co-shareholders, I welcome everyone. Good afternoon, sir. It is a matter of great joy, when we saw your results for the June quarter, your revenue is good, profits have also increased. And regarding this acquisition you are doing of the company Anand Chemiceutics, after that, how will our revenue increase going forward? And sir, what difference will come in the margin going forward? In what manner will our EPS increase? This acquisition that we have been doing of Anand Chemiceutics, if you could please tell a little about this, then we will get more information about the company. Apart from that, from your remarks, we got to know a lot about the company's present and future, which you told us in your Chairman's speech. Apart from that, going forward, may the company make progress, this is what we hope from you and pray to God. The secretarial department, the way they prepared the balance sheet well in time and introduced us to you, many thanks to them. This time that we have shared with you today, in the coming time, will strengthen our investment. Thank you to the management team. Thank you to the secretarial team. Thank you, sir. Thank you.

Moderator: Thank you. Our next speaker shareholder, Monu Pruthi Sandeep Kumar, kindly accept the prompt on your screen, turn on your audio and video, and you may please proceed with your question.

Sandeep Kumar: Hello.

Moderator: Yes, sir, we can hear you.

Sandeep Kumar: Audible?

Moderator: Yes, sir, you are. Please go ahead.

Sandeep Kumar: Sir, greetings. I, Sandeep Kumar, being an old shareholder, express my thanks. Hello?

Moderator: Sir, we can hear you. You may please proceed ahead with the question. It seems there is a technical issue from the current speaker shareholder. We'll move forward to the next speaker shareholder, Mr. Pramod Kumar Jain. Kindly accept the prompt on your screen, turn on your audio and video, and you may please proceed ahead with the question. Thank you.

Pramod Kumar Jain: Can you hear me?

Moderator: Yes, sir, we can hear you. Yes.

Pramod Kumar Jain: Greetings. I am Pramod Jain from Delhi. I thank the Chairman sir, Board of Directors, and secretarial department very much. You gave me the opportunity to speak in this AGM, and I support all the resolutions proposed today. Sir, I want to know, the company's standalone quarterly net profit has decreased by 50% from approximately INR6.96 crores in June 2025 to approximately INR 3.50 crores in June 2026. What is the main reason for this decline? And what steps are being taken to improve it? Number two, the management, without any new acquisition, has set a target of 23% consolidated revenue growth and 5% EBITDA margin for the financial year 2027. What is the concrete plan to achieve this target? Number three, the company has recently bought stakes in companies like Peerless Biotech, Ujjain Maheshwari firm, and Anand Chemiceutics. What impact will these acquisitions have on the company's asset base and total market share? Lastly, in the pharma and healthcare sector, 10 to 15-minute delivery is increasing rapidly. Since there are more than 75,000 SKUs in the pharma market, how will the company tackle the challenges of delivery cost and order value? Thank you, greetings. In the end, I will thank the secretarial department very much, who helped me a lot in connecting to this portal. Greetings, Jai Jinendra.

Moderator: Thank you. Our next speaker shareholder, Mr. Gaurav Kumar Singh, kindly accept the prompt on your screen, turn on your audio and video, and you may please proceed with your question.

Gaurav Kumar Singh: Hello. Am I audible, sir?

Moderator: Yes, you are.

Gaurav Kumar Singh: Okay. Thank you so much. Respected Chairman, Board of Directors, and fellow shareholders, a good afternoon to all of you. Myself Gaurav Kumar Singh, joining this AGM from Delhi. First of all, I would like to thank the management for giving me this opportunity to express my views on this platform. As a long-term investor, I would like to know that how the board plans to maximize shareholder value over the next five years. And second is, how much of new customer acquisition is coming through digital channels, and what investments are planned to strengthen direct and online business? As far as the agenda of this AGM is concerned, I support all the resolutions along with all my family members. I sincerely thank the management and all the employees of the company for their dedication and hard work. I wish you continued success and hope the company achieves even greater milestones in the years ahead. With this, I also thank our CFO, the Company Secretary, and his entire secretarial team for maintaining high standard of corporate governance. In the end, I wish a bright future for the company and a great health for all of you. Thank you, sir. Jai Hind.

Moderator: Thank you. Ladies and gentlemen, that was the last speaker shareholder. I now hand the proceeding to the management. Thank you, and over to you team.

Sujesh Vasudevan: We'll now respond to the queries raised by the speaker shareholders.

Prabhat Agrawal: Thank you, everyone, for putting your valuable questions to us. I'll try to summarize. Some of the questions were really focused about growth, profitability, how do we enhance our margins, how do we ensure that we continue to grow, right? And my simple answer is that this is a huge industry, a very large-size industry in which we have a very unique value proposition, which helps us to grow at a rate higher than the industry growth rate and with the scale up of business, the margins continue to expand. We are getting into more higher margin segments of the industry like medical technologies, which we talked about in my speech as well, in Chairman's speech as well. So, all these initiatives will help us to deliver a margin which is higher than the last year. In our guidance also that we have released to all the investors in the company that this year we target or aim to grow at 23% growth rate, enhance our margins from last year's 4% to 5% in this year. So, many steps are being taken by the company and the management to ensure that we continue to beat the industry growth rate and expand our margins simultaneously. Some of the questions were around buyback, dividend, and things like that. And what I would like to say that the company is in a very, very high-growth phase. In the last three, four years, our growth rate is in 30%, in excess of 30%. So, company is continuously investing its capital in growing the business. There is a large market opportunity out there, and we are uniquely positioned to capture that opportunity. So, most of our capital is going, or retained profits are going in reinvestment towards capturing that opportunity. When time comes, when the board decides, we would evaluate options on a buyback and a dividend payment. Some of the questions were around digital technology, how we are using AI or how, what kind of business we are generating through digital channels. I would like to say that technology is a core pillar of Entero, and we are using data analytics, AI, everything to garner more market share. Our customer engagement with the customers is using digital channels to capture their orders, their volumes. We are using AI to analyze our data to give more meaningful decision, more meaningful analysis and outcome that can help us to effectively compete in the market. Broadly, these were the questions. If some of your question has remained unanswered, then please feel free to reach out to our secretarial team or to our investor relation department. Thank you.

Sujesh Vasudevan: Thanks. I would now like to thank all the speaker shareholders for their comments and expressing their views. I hereby authorize Ms. Sanu Kapoor, Company Secretary, to receive, accept, and countersign the scrutinizer's report and declare the consolidated voting results of the remote e-voting and e-voting conducted during this meeting. On behalf of the Board of Directors, I extend my sincere thanks to all our members and fellow board members for attending this meeting. I would also like to express our gratitude to all our stakeholders for their continued trust, confidence, and support. Members may kindly note that the e-voting will remain open for the next 15 minutes for voting by those members who have not yet cast their votes, and the meeting will stand concluded thereafter. Thank you, everyone. Have a good day.